drugset

drugset / Trial / NCT00104078

Study Evaluating MYO-029 in Adult Muscular Dystrophy

NCT00104078 ↗

Phase 1/2 Completed 108 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Timeline

Start: 2005-02
Primary completion: —
Completion: 2007-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	STAMULUMAB	Monoclonal antibody	—	—

Indications